Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS JANUARY ISSUE PUBLISHED
  • JANUARY 2021 Issue has been successfully launched on 1 January 2021.

Abstract

BIOEQUIVALENCE STUDY OF TWO INJECTABLE TULATHROMYCIN FORMULATIONS (DRAXXIN® AND DRAXIFAR®) IN CALVES

Ashraf Elkomy* and Mohamed Aboubakr

ABSTRACT

The present study was designed to assess the comparative bio-equivalence of Draxxin® and Draxifar® in healthy calves after intramuscular injection (IM) of both products in a dose of 2.5 mg tulathromycin/kg b.wt. Ten calves were divided into two groups. The first group was designed to study the pharmacokinetics of Draxxin®, while the 2nd group was designed to study the pharmacokinetics of Draxifar®. Each calves in both groups was IM injected with 2.5 mg tulathromycin/kg b.wt. Blood samples were obtained from the jugular vein and collected immediately before and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 and 132 hours after a single IM injection. The disposition kinetics of Draxxin® and Draxifar® following IM injection of 2.5 mg tulathromycin/kg b.wt, revealed that the maximum blood concentration of tulathromycin [Cmax] were 0.57 and 0.55 μg/ml and attained at [tmax] of 3.56 and 3.63 hours, for Draxxin® and Draxifar® respectively. In conclusion: Draxifar® is bioequivalent to Draxxin® since the ratios of Cmax, AUC0-132 and AUC0-∞ (T/R) for tulathromycin was 0.96, 0.89 and 0.89, respectively. These are within the bioequivalence acceptance range. Draxifar® and Draxxin® are therefore bioequivalent and interchangeable in calves.

Keywords: .


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More